SB649868
From Wikipedia, the free encyclopedia
SB649868 is an orexin receptor antagonist in development by GlaxoSmithKline. Currently in Phase 2 development, this drug for sleep disorders is one of two such compounds currently in development, the other being Actelion's ACT-078573.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
